CHMP Backs Keytruda Combo for Bladder Cancer: Incremental Positive Amid Transition

What happened

The European Medicines Agency's CHMP recommended approval of Merck's Keytruda in combination with Padcev for certain bladder cancer patients, providing a modest regulatory win for the franchise. This label expansion supports Keytruda's near-term commercial durability but does not address the core investment thesis: Keytruda still represents 49% of sales, and the company faces a ~$2.5B headwind in 2026 from generics and IRA pricing, while the Gardasil China pause remains unresolved. The recommendation is a positive data point for the franchise's regulatory strategy, but it does not alter the fundamental timeline of biosimilar competition and IRA pricing expected in 2028-2029. The pipeline's ability to fill the post-Keytruda gap depends on launches like Winrevair and Capvaxive scaling, which have yet to deliver material financial proof. Thus, while the CHMP news is a modest positive, it does not shift the risk/reward calculus or warrant a change in the current WAIT rating.

Implication

The CHMP recommendation supports Keytruda's commercial durability but does not change the fundamental timeline of LOE risks. Investors should view this as incremental validation of the franchise's regulatory strategy, not a catalyst for re-rating. The re-assessment window remains tied to 2026 headwind containment and Gardasil China restart visibility.

Thesis delta

No shift. The CHMP backing is a positive data point for Keytruda's label expansion but does not alter the underlying thesis that MRK's near-term returns depend on containing ~$2.5B headwinds and resolving the Gardasil China pause. The stock's WAIT rating and conviction level remain unchanged.